Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets. Its Analytical Instruments segment provides instruments, consumables, software, and services for pharmaceutical, biotechnology, academic, government, environmental, and other research and industrial markets, as well as clinical laboratories. The company's Specialty Diagnostics segment offers liquid, ready-to-use, and lyophilized immunodiagnostic reagent kits, as well as calibrators, controls, protein detection assays, and instruments; immunodiagnostics develops, manufactures and markets complete bloodtest systems to support the clinical diagnosis and monitoring of allergy, asthma and autoimmune diseases; dehydrated and prepared culture media, collection and transport systems, instrumentation, and consumables; human leukocyte antigen typing and testing for organ transplant market; and healthcare products. Its Laboratory Products and Biopharma Services segment provides laboratory products, research and safety market channel, and pharma services and clinical research. It offers products and services through a direct sales force, customer-service professionals, electronic commerce, and third-party distributors under Thermo Scientific; Applied Biosystems; Invitrogen; Fisher Scientific; Unity Lab Services; and Patheon and PPD. Thermo Fisher Scientific Inc. was founded in 1956 and is headquartered in Waltham, Massachusetts.
Employees - 122000,
CEO - Mr. Marc N. Casper,
Sector - Healthcare,
Country - US,
Market Cap - 203.30B
Altman ZScore(max is 10): 3.86, Piotroski Score(max is 10): 5, Working Capital: $9182000000, Total Assets: $100364000000, Retained Earnings: $51421000000, EBIT: 8109000000, Total Liabilities: $51265000000, Revenue: $42370000000
AryaFin Target Price - $823.66 - Current Price $524.05 - Analyst Target Price $657.08
Ticker | TMO |
Index | S&P 500 |
Curent Price | 524.05 |
Change | 1.42% |
Market Cap | 203.30B |
Average Volume | 1.73M |
Income | 6.14B |
Sales | 42.37B |
Book Value/Share | 128.08 |
Cash/Share | 17.16 |
Dividend Est | 1.56 (0.30%) |
Dividend TTM | 1.56 (0.30%) |
Dividend Ex-Date | Dec 13, 2024 |
Employees | 122000 |
Moving Avg 20days | -0.28% |
Moving Avg 50days | -3.77% |
Moving Avg 200days | -8.69% |
Shares Outstanding | 382.50M |
Earnings Date | Oct 23 BMO |
Inst. Ownership | 90.13% |
Price/Earnings | 32.86 |
Forwad P/E | 22.39 |
PE Growth | 5.15 |
Price/Sales | 4.80 |
Price/Book | 4.09 |
Price/Cash | 30.54 |
Price/FCF | 26.15 |
Quick Ratio | 1.26 |
Current Ratio | 1.63 |
Debt/Equity | 0.72 |
Return on Assets | 6.22% |
Return on Equity | 13.01% |
Return on Investment | 7.65% |
Gross Margin | 39.76% |
Ops Margin | 17.41% |
Profit Margin | 14.48% |
RSI | 45.06 |
BETA(β) | 0.77 |
From 52week Low | 6.23% |
From 52week High | -16.54% |
EPS | 15.95 |
EPS next Year | 23.40 |
EPS next Qtr | 5.95 |
EPS this Year | 0.70% |
EPS next 5 Year | 6.38% |
EPS past 5 Year | 16.37% |
Sales past 5 Year | 12.53% |
EPS Y/Y | 4.36% |
Sales Y/Y | -2.42% |
EPS Q/Q | -3.97% |
Sales Q/Q | 0.23% |
Sales Surprise | -0.34% |
EPS Surprise | 0.72% |
ATR(14) | 11.08 |
Perf Week | -0.54% |
Perf Month | 2.19% |
Perf Quarter | -14.14% |
Perf Year | 0.89% |
Perf YTD | -1.27% |
Target Price | 657.08 |
AryaFin Engine© - An AI FinTech Venture - 2024 Disclaimer